Skip to main content
Equibles
IPSC logo

IPSC · Century Therapeutics, Inc. · Metrics

Track IPSC — free

Use IPSC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IPSC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.63 -0.11 (-6.32%) At close · Nov 12
Russell 2000 member Rebalance outlook locked
Market Cap
$296.00M
Shares
181.60M
Volume · Nov 12 608.76K Avg daily vol (3M) 719.15K

IPSC metrics

73 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.63
Market cap
$296.00M

Price action

23 metrics
Price change (1W)
+4.2%
Price change (30D)
+26.1%
Price change (3M)
-11.2%
Price change (6M)
-23.7%
Price change (YTD)
+74.9%
Price change (1Y)
+209.1%
Trailing year
Price change (5Y)
-91.7%
52-week high
$2.94
52-week low
$0.47
Change from 52-week high
-40.8%
Change from 52-week low
+274.2%
Annualized volatility
102.7%
Annualized volatility (3M)
81.9%
Implied volatility (30D)
116.3%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
2.2
RSI (14D)
56.7
Price vs SMA 50
+4.7%
Price vs SMA 200
-15.9%
Avg volume (3M)
717,943
Relative volume
0.5
Average dollar volume
$1.19M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
181.60M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.9×
reciprocal yield 34.6%
P / book
1.4
reciprocal yield 73.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-34.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
-15.3×
EV / revenue historical average (5Y)
-15.3×
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-03-19

Profitability

9 metrics
Gross margin
—
Operating margin
-15.8%
Trailing 12 months
Net margin
-8.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$116.99M
Net income (TTM)
−$109.79M
Trailing 12 months
Diluted EPS (TTM)
$-0.93
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$1.27
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.95
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.90
Operating cash flow per diluted share (TTM)
$-0.71
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.67
Stock compensation per diluted share (TTM)
$0.04
Book value per share
$1.82

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$109.16M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+138.6%
Year over year · more shares
Revenue CAGR (3Y)
+175.9%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-47.3%
Return on assets
-38.3%
Debt / equity
—
Current ratio
8.3
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
8.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$49.64M
Total assets
$287.01M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$86.76M
Capital expenditures (TTM)
$1.33M
R&D (TTM)
$78.93M
SG&A (TTM)
—
Stock compensation (TTM)
$5.59M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
100
13F filer change QoQ
+28
Institutional ownership
87.2%
Conviction holders (share of 13F filers)
2.0%
Crowding (high-turnover and private-fund holders)
55.5%
Private-fund adviser ownership
55.4%
Active holders' share change QoQ
+6.8%
Holder tenure
3.9
Price vs estimated holder cost
+18.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
6.7%

Short interest

3 metrics
Short interest
17.6%
Latest settlement · 31.0 days to cover
Days to cover
31.0d
Short-squeeze score
88 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$10,212
Insider-sentiment score
46 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1850119 CUSIP 15673T100 13F (30d) 55 filings 41 filers Visit website Investor relations